Prosensa

Prosensa Announces Intent to Voluntarily Delist From NASDAQ
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
Yahoo
Prosensa
NASDAQ
Flag link:
Booming biotechs bank $2.7B in follow-on cash
Booming biotechs bank $2.7B in follow-on cash
Fierce Biotech
biotech
Prosensa
Biomarin
Zafgen
Alnylam
Auspex
Puma Biotechnology
Arena Pharmaceuticals
Radius Health
Intrexon
Flag link:
Update: BioMarin To Acquire Prosensa Holding N.V.
Update: BioMarin To Acquire Prosensa Holding N.V.
Seeking Alpha
Biomarin
Prosensa
M&A
Flag link:
The Best-Performing Biotechnology Stocks Of 2014
The Best-Performing Biotechnology Stocks Of 2014
Forbes
biotech
Avanir
OvaScience
Agios
Bluebird Bio
Receptos
Prosensa
Pernix
Achillion
Amicus Therapeutics
CytoSorbents
PTC Therapeutics
Flag link:
The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers
The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers
24/7 Wall St
Agios Pharmaceuticals
OvaScience
Radius
Prosensa
TG Therapeutics
Bluebird Bio
Receptos
Flag link:
BioMarin CEO Sees Big Future For Prosensa Drug
BioMarin CEO Sees Big Future For Prosensa Drug
Investors.com
Biomarin
Prosensa
drisapersen
Duchenne Muscular Dystrophy
Flag link:
The Nominees for Best Biotechnology Co. CEO of 2014 Are...
The Nominees for Best Biotechnology Co. CEO of 2014 Are...
TheStreet.com
biotech
EXACT Sciences
Idenix
Prosensa
Agios Pharmaceuticals
Bluebird Bio
InterMune
Flag link:
BioMarin Expands Reach By Buying Prosensa for Up to $840 Million
BioMarin Expands Reach By Buying Prosensa for Up to $840 Million
TheStreet.com
Biomarin
Prosensa
M&A
Flag link:
Prosensa heads to the FDA with its once-failed DMD treatment
Prosensa heads to the FDA with its once-failed DMD treatment
Fierce Biotech
Prosensa
FDA
Duchenne Muscular Dystrophy
drisapersen
Flag link:
Prosensa declares progress on drug target for Duchenne
Prosensa declares progress on drug target for Duchenne
Pharmaphorum
Prosensa
Duchenne Muscular Dystrophy
Flag link:
Prosensa picks up $7M to speed up DMD development
Prosensa picks up $7M to speed up DMD development
Fierce Biotech
Duchenne Muscular Dystrophy
Prosensa
Flag link:
Tuesday’s Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology
Tuesday’s Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology
Motley Fool
Vanda
Prosensa
Clovis Oncology
Hetlioz
CO-1686
drisapersen
Flag link:
Prosensa to Seek U.S. Approval for DMD Drug
Prosensa to Seek U.S. Approval for DMD Drug
TheStreet.com
Duchenne Muscular Dystrophy
Prosensa
drisapersen
Flag link:
Prosensa jumps 30% after data from Phase 2 study of DMD drug
Prosensa jumps 30% after data from Phase 2 study of DMD drug
The Fly on the Wall
Prosensa
Duchenne Muscular Dystrophy
drisapersen
Sarepta Therapeutics
Flag link:
GSK hands back failed muscular dystrophy drug to Prosensa
GSK hands back failed muscular dystrophy drug to Prosensa
Yahoo/Reuters
GSK
Prosensa
Duchenne Muscular Dystrophy
drisapersen
Flag link:
A Chart You Should See: Biotech IPO Class of 2013 Is Lagging
A Chart You Should See: Biotech IPO Class of 2013 Is Lagging
TheStreet.com
IPOs
Bluebird Bio
Enanta
Portola Pharmaceuticals
Prosensa
Flag link:
This Slide Paints Grim Picture of Glaxo, Prosensa's DMD Drug
This Slide Paints Grim Picture of Glaxo, Prosensa's DMD Drug
TheStreet.com
GSK
Prosensa
Duchenne Muscular Dystrophy
drisapersen
Sarepta Therapeutics
eteplirsen
Flag link:
The Rosen Law Firm Announces Investigation of Shareholder Securities Claims Against Prosensa Holding NV – RNA
The Rosen Law Firm Announces Investigation of Shareholder Securities Claims Against Prosensa Holding NV – RNA
Yahoo/BusinessWire
Prosensa
lawsuits
Flag link:
Phase III Trial Ruins Prosensa's Drisapersen, Sarepta Rallies Strongly
Phase III Trial Ruins Prosensa's Drisapersen, Sarepta Rallies Strongly
Seeking Alpha
Prosensa
Sarepta Therapeutics
drisapersen
GSK
Duchenne Muscular Dystrophy
Flag link:
3 Horrendous Health-Care Stocks This Week
3 Horrendous Health-Care Stocks This Week
Motley Fool
Prosensa
GSK
Sarepta Therapeutics
Questcor Pharmaceuticals
Flag link:

Pages